Skip to main content

Table 1 Basic characteristics of the study groups

From: Left ventricular myocardial deformation assessment in asymptomatic patients with recently diagnosed sarcoidosis of the respiratory tract and/or extrapulmonary sarcoidosis

  Sarcoidosis n = 113 Control group n = 22 p value
Age [years] 52.0 ± 10.8 52.7 ± 11.1 0.78
Female [n (%)] 51 (45.1%) 8 (36.4%) 0.49
BMI [kg/m2] 29.1 ± 4.4 26.4 ± 4.7 9.10–3
Dyspnoea [n (%)] 58 (60.2%) 1 (4.6%)  < 10–5
Hypertension [n (%)] 35 (31.0%) 7 (31.8%) 1.00
Diabetes [n (%)] 6 (5.3%) 0 (0.0%) 0.59
Corticosteroids [n (%)] 64 (56.6%) 1 (4.6%)  < 10–5
ACE-inhibitors [n (%)] 14 (12.4%) 4 (18.2%) 0.49
ARBs [n (%)] 13 (11.5%) 0 (0.0%) 0.13
β-blockers [n (%)] 16 (14.2%) 1 (4.6%) 0.31
Diuretics [n (%)] 5 (4.4%) 1 (4.6%) 1.00
Statins [n (%)] 11 (9.7%) 1 (4.6%) 0.69
LV EF [%] 66 ± 7 65 ± 5 0.29
  1. Variables marked in bold have p-value < 0.05
  2. Continuous variables are expressed as the mean ± standard deviation, binary variables as count (percentage). The p values refer to the t test in the case of continuous variables or to the Fisher exact test in binary variables
  3. BMI body mass index, ACE angiotensin converting enzyme, ARBs angiotensin receptor blockers, LV left ventricle, EF ejection fraction